← Trials/Trial dossier/NCT06774807

GLP-2ant

CompletedPhase NA

Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)

Antagonist of the Glucagon-like Peptide 2 (GLP-2) Receptor

Lead sponsor

University of Copenhagen

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criterion

•BMI 19-28

Primary endpoint

•SMA blood flow

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06774807

Org study IDH-24000668

Timeline

Milestones

Study start2024-05-01actual

Primary completion2024-09-01actual

Study completion2024-09-07actual

Study first posted2025-01-14actual

Last update posted2025-05-02actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Age 18-70 years

•BMI 19-28 kg/m2

Exclusion criteria

•Chronic illness that affects the cardiovascular system or gastrointestinal tract

•Treatment with medicine or supplements that cannot be paused for 12 hours

•Intake of above 14 alcoholic drinks per week or substance abuse

•Liver enzymes (ALAT) above 2 times normal values

•Decreased kidney function (eGFR below 90 or creatinine levels over reference value)

•Low blood percentage (hemoglobin below reference value)

•Any condition or disease that the persons responsible for the study find would interfere with the participation of the study.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

SMA blood flow

Time frame:85 minutes

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

PVblood flow

Time frame:85 minutes

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.